Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Free Cash Flow (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Free Cash Flow for 6 consecutive years, with -$10.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 64.13% to -$10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$50.0 million, a 49.83% increase, with the full-year FY2025 number at -$50.0 million, up 49.83% from a year prior.
  • Free Cash Flow was -$10.6 million for Q4 2025 at PROCEPT BioRobotics, down from -$2.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$2.7 million in Q3 2025 to a low of -$42.2 million in Q4 2023.
  • A 5-year average of -$21.2 million and a median of -$18.3 million in 2025 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 125.68% in 2023, then skyrocketed 87.65% in 2025.
  • PROCEPT BioRobotics' Free Cash Flow stood at -$16.5 million in 2021, then tumbled by 63.36% to -$26.9 million in 2022, then plummeted by 56.56% to -$42.2 million in 2023, then surged by 30.02% to -$29.5 million in 2024, then surged by 64.13% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Free Cash Flow are -$10.6 million (Q4 2025), -$2.7 million (Q3 2025), and -$18.3 million (Q2 2025).